What's changed? And what would you say in your observation is driving the momentum? Yeah.

Yeah, there is a lot of CMT drug development happening.

And I think the first, well, there's many things that really come together, I think, to push the momentum.

And I think the first thing we already mentioned, that we've identified a lot of the genetic causes for a lot of the subtypes.

Of course, there's more that we need to find.

We understand the underlying biology of a lot of these subtypes.

And so that gives researchers the opportunity to really focus on particular mechanisms and have a really focused topic for their research.

Brian, there are clearly lots of exciting innovations happening in research around therapeutics for CMT, what do you think are some of the most promising approaches that are currently being explored? And can you explain how these different strategies are intended to work?